| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25057 |
| Drug |
Teprotumumab |
| Brand |
Tepezza® |
| Indication |
Teprotumumab (Tepezza®) is indicated in adults for the treatment of moderate to severe thyroid eye disease. |
| Rapid review commissioned |
16/09/2025 |
| Rapid review completed |
15/10/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of teprotumumab compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE |
29/10/2025 |
